Skip to content

The psychotropic drug dopamine PET study

A arndomiozed, placebo-controlled, double-blind, comparative study of quantification of the effects of tramadol and sertraline on the dopmaine nervous system using PET in healthy adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031190184
Enrollment
6
Registered
2020-01-20
Start date
2020-01-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy healthy

Interventions

Take the 3 drugs, respectively, then PET using [18F] FE-PE2I is performed for 60 minutes from the time when the maximum blood concentration is reached after taking the drugs. 1. tramadol 100 mg 2. ser

Sponsors

Yoshiro Okubo
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Subjects who are 20 years old or older and younger than 40 years old when obtaining consent 2) Subjects with no hisotry of psychiatric disorders 3) Subjects with normal BMI (18.5-25) 4) Subjects without the history of smoking 5) Subjects who have the ability to provide informed consent and adhere to the protocol.

Exclusion criteria

Exclusion criteria: 1) Subjects with drug allergy 2) Subjects who have gastrointestinal symptoms when taking lactose 3) Subjects taken contraindications for the study drug within 2 weeks prior to obtaining consent 4) Subjects who is contrainidicated for the use of MRI 5) Subjects with the history of smoking, or who took cafefin (by 2 days before PET), or alcohol (by the day before PET) 6) Athletes at the competition level 7) Subjects who has been exposed to radiation by job-related exposure or therapy in one year exceeding 15mSv 8) Subjects who do not agree to notify the results of the examination which requires treatment. 9) Subjects who are judged as not suitable for participation in this study

Design outcomes

Primary

MeasureTime frame
the change of binding potential of dopamin transporter

Secondary

MeasureTime frame
blood drug concentration evaluation of higher brain function (neuropsychological examination)

Contacts

Public ContactAmane Tateno

Department of Neuropsychiatry

amtateno@nms.ac.jp+81-3-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026